219 related articles for article (PubMed ID: 35343197)
21. Clinical characteristics, treatment patterns, and outcomes in adult patients with germline
Obeid E; Parikh RC; Esterberg E; Arondekar B; Hitchens A; Arruda LS; Niyazov A; Whitaker K
Front Oncol; 2024; 14():1341665. PubMed ID: 38817906
[TBL] [Abstract][Full Text] [Related]
22. PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers.
Collet L; Péron J; Penault-Llorca F; Pujol P; Lopez J; Freyer G; You B
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158866
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
Moy B; Rumble RB; Come SE; Davidson NE; Di Leo A; Gralow JR; Hortobagyi GN; Yee D; Smith IE; Chavez-MacGregor M; Nanda R; McArthur HL; Spring L; Reeder-Hayes KE; Ruddy KJ; Unger PS; Vinayak S; Irvin WJ; Armaghani A; Danso MA; Dickson N; Turner SS; Perkins CL; Carey LA
J Clin Oncol; 2021 Dec; 39(35):3938-3958. PubMed ID: 34324366
[TBL] [Abstract][Full Text] [Related]
24. Real-world data in patients with
Beas-Lozano EL; Verduzco-Aguirre HC; Gonzalez-Salazar R; Chavarri-Guerra Y
Ecancermedicalscience; 2023; 17():1633. PubMed ID: 38414963
[TBL] [Abstract][Full Text] [Related]
25. Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer.
Le D; Gelmon KA
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):833-839. PubMed ID: 30118334
[TBL] [Abstract][Full Text] [Related]
26. Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer.
Anders CK; Winer EP; Ford JM; Dent R; Silver DP; Sledge GW; Carey LA
Clin Cancer Res; 2010 Oct; 16(19):4702-10. PubMed ID: 20858840
[TBL] [Abstract][Full Text] [Related]
27. Poly(ADP-ribose) polymerase inhibitors in the treatment landscape of triple-negative breast cancer (TNBC).
El Gazzar WB; Albakri KA; Hasan H; Badr AM; Farag AA; Saleh OM
J Oncol Pharm Pract; 2023 Sep; 29(6):1467-1479. PubMed ID: 37559370
[TBL] [Abstract][Full Text] [Related]
28. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
[TBL] [Abstract][Full Text] [Related]
29. Advances in Targeted Therapies for Triple-Negative Breast Cancer.
McCann KE; Hurvitz SA; McAndrew N
Drugs; 2019 Jul; 79(11):1217-1230. PubMed ID: 31254268
[TBL] [Abstract][Full Text] [Related]
30. Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer.
Chu YY; Yam C; Chen MK; Chan LC; Xiao M; Wei YK; Yamaguchi H; Lee PC; Han Y; Nie L; Sun X; Moulder SL; Hess KR; Wang B; Hsu JL; Hortobagyi GN; Litton J; Chang JT; Hung MC
Am J Cancer Res; 2020; 10(2):648-661. PubMed ID: 32195033
[TBL] [Abstract][Full Text] [Related]
31. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
Okuma HS; Yonemori K
Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
[TBL] [Abstract][Full Text] [Related]
32. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.
von Minckwitz G; Müller BM; Loibl S; Budczies J; Hanusch C; Darb-Esfahani S; Hilfrich J; Weiss E; Huober J; Blohmer JU; du Bois A; Zahm DM; Khandan F; Hoffmann G; Gerber B; Eidtmann H; Fend F; Dietel M; Mehta K; Denkert C
J Clin Oncol; 2011 Jun; 29(16):2150-7. PubMed ID: 21519019
[TBL] [Abstract][Full Text] [Related]
33. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
34. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
Li Y; Liu CF; Rao GW
Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
[TBL] [Abstract][Full Text] [Related]
35. Talazoparib to treat BRCA-positive breast cancer.
Guney Eskiler G
Drugs Today (Barc); 2019 Jul; 55(7):459-467. PubMed ID: 31347614
[TBL] [Abstract][Full Text] [Related]
36. Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer.
Kelly CM; Buzdar AU
Drugs; 2013 May; 73(6):505-15. PubMed ID: 23605692
[TBL] [Abstract][Full Text] [Related]
37. Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic
Schwartzberg LS; Kiedrowski LA
Ther Adv Med Oncol; 2021; 13():17588359211006962. PubMed ID: 33868464
[TBL] [Abstract][Full Text] [Related]
38. State of art of advanced triple negative breast cancer.
Khosravi-Shahi P; Cabezón-Gutiérrez L; Aparicio Salcedo MI
Breast J; 2019 Sep; 25(5):967-970. PubMed ID: 31155832
[TBL] [Abstract][Full Text] [Related]
39. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R
Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer.
Zhu X; Chen L; Huang B; Li X; Yang L; Hu X; Jiang Y; Shao Z; Wang Z
J Exp Clin Cancer Res; 2021 Apr; 40(1):122. PubMed ID: 33832512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]